KA
GILD icon

Klingman & Associates’s Gilead Sciences GILD Stock Holding History

Klingman & Associates’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$369K Buy
2,645
+119
+5% +$16.7K 0.02% 233
2025
Q4 		$310K Buy
2,526
+211
+9% +$25.6K 0.02% 250
2025
Q3 		$257K Buy
+2,315
New +$263K 0.01% 285
2016
Q4 		– Sell
-100
Closed -$8K – 180
2016
Q3 		$8K Hold
100
– – ﹤0.01% 302
2016
Q2 		$8K Hold
100
– – ﹤0.01% 306
2016
Q1 		$9K Hold
100
– – ﹤0.01% 300
2015
Q4 		$10K Hold
100
– – ﹤0.01% 301
2015
Q3 		$9K Hold
100
– – ﹤0.01% 313
2015
Q2 		$12K Hold
100
– – ﹤0.01% 294
2015
Q1 		$10K Buy
+100
New +$10.2K ﹤0.01% 277

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Klingman & Associates's GILD Position: Q1 2026 in Review

Klingman & Associates increased its Gilead Sciences (GILD) stake by 4.7% in Q1 2026, buying an estimated $16.7K and bringing the position to 2,645 shares worth $369K. The position accounts for 0.02% of the portfolio, ranked #233.

Klingman & Associates first reported a position in GILD in Q1 2015 and has held it in 10 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Klingman & Associates held 2,645 shares of Gilead Sciences worth $369K as of Q1 2026.
  • Klingman & Associates bought 119 Gilead Sciences shares in Q1 2026, an estimated $16.7K.
  • Gilead Sciences made up 0.02% of Klingman & Associates's portfolio in Q1 2026, its #233 holding.
  • Klingman & Associates first reported a position in Gilead Sciences in Q1 2015 and has held it in 10 quarters since.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Klingman & Associates's 13F filing for Q1 2026, filed 14 May 2026.